Winnow Wealth LLC Acquires Shares of 24,204 Exelixis, Inc. $EXEL

Winnow Wealth LLC bought a new position in shares of Exelixis, Inc. (NASDAQ:EXEL) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 24,204 shares of the biotechnology company’s stock, valued at approximately $1,017,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of EXEL. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Exelixis by 81.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,181 shares of the biotechnology company’s stock worth $1,592,000 after purchasing an additional 19,407 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Exelixis by 4.9% in the first quarter. Goldman Sachs Group Inc. now owns 1,466,779 shares of the biotechnology company’s stock valued at $54,153,000 after buying an additional 68,133 shares during the last quarter. Focus Partners Wealth boosted its stake in shares of Exelixis by 83.4% during the first quarter. Focus Partners Wealth now owns 38,458 shares of the biotechnology company’s stock worth $1,420,000 after buying an additional 17,483 shares during the period. Geneos Wealth Management Inc. grew its holdings in shares of Exelixis by 134.3% during the first quarter. Geneos Wealth Management Inc. now owns 1,647 shares of the biotechnology company’s stock worth $61,000 after buying an additional 944 shares during the last quarter. Finally, Sivia Capital Partners LLC grew its holdings in shares of Exelixis by 23.8% during the second quarter. Sivia Capital Partners LLC now owns 14,362 shares of the biotechnology company’s stock worth $633,000 after buying an additional 2,764 shares during the last quarter. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Exelixis Stock Down 2.2%

Shares of NASDAQ EXEL opened at $41.36 on Friday. The stock has a market capitalization of $11.09 billion, a price-to-earnings ratio of 17.45, a price-to-earnings-growth ratio of 0.76 and a beta of 0.40. Exelixis, Inc. has a 52 week low of $32.38 and a 52 week high of $49.62. The firm has a 50-day moving average price of $43.76 and a 200 day moving average price of $41.06.

Exelixis (NASDAQ:EXEL) last issued its earnings results on Tuesday, November 4th. The biotechnology company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.68 by $0.10. The company had revenue of $597.76 million during the quarter, compared to analysts’ expectations of $590.04 million. Exelixis had a net margin of 29.63% and a return on equity of 31.06%. The firm’s quarterly revenue was up 10.8% compared to the same quarter last year. During the same period last year, the company posted $0.47 earnings per share. Equities research analysts expect that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Insider Transactions at Exelixis

In other Exelixis news, Director Stelios Papadopoulos sold 100,000 shares of the firm’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $43.55, for a total transaction of $4,355,000.00. Following the completion of the transaction, the director directly owned 1,189,228 shares in the company, valued at approximately $51,790,879.40. This trade represents a 7.76% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Mary C. Beckerle sold 24,622 shares of the company’s stock in a transaction dated Tuesday, November 11th. The shares were sold at an average price of $41.93, for a total transaction of $1,032,400.46. Following the completion of the sale, the director directly owned 21,380 shares in the company, valued at $896,463.40. This trade represents a 53.52% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 245,235 shares of company stock worth $10,490,600. Corporate insiders own 2.82% of the company’s stock.

Analysts Set New Price Targets

EXEL has been the subject of a number of recent research reports. UBS Group set a $41.00 price objective on Exelixis in a research report on Monday, January 5th. Citigroup lowered shares of Exelixis from a “market outperform” rating to an “underperform” rating in a research report on Monday, January 5th. Oppenheimer restated a “market perform” rating and set a $36.00 price objective on shares of Exelixis in a research report on Wednesday, November 5th. Wolfe Research began coverage on shares of Exelixis in a research note on Tuesday, November 18th. They issued a “peer perform” rating for the company. Finally, Wells Fargo & Company dropped their price target on shares of Exelixis from $36.00 to $30.00 and set an “equal weight” rating on the stock in a research note on Tuesday, October 21st. Eleven analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $45.95.

Exelixis Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.